Quark Venture

Sitka Biopharma Inc. is a preclinical biotechnology company based in Vancouver, Canada, founded in 2013. The company specializes in developing a novel nanoparticle platform technology aimed at enhancing drug absorption in challenging-to-penetrate tissues. Its lead candidate, STK-01, targets the absorption issues associated with intravesical chemotherapy for bladder cancer, addressing the limitations of current therapies that often face significant uptake and tolerability challenges. Sitka Biopharma's technology is designed to deliver a higher concentration of the chemotherapeutic agent docetaxel directly into the bladder wall, thereby improving treatment outcomes. The platform is also being explored for future applications in intraperitoneal delivery for ovarian cancer, showcasing its versatility in treating localized diseases where local administration is feasible yet currently ineffective.

Founded in 2013, Canary Medical specializes in developing implantable sensor technology for remote patient monitoring. Its flagship product, canturio™te, is the world's first 'smart knee' tibial extension that monitors joint performance and transmits data to the cloud autonomously.

Sitka Biopharma Inc. is a preclinical biotechnology company based in Vancouver, Canada, founded in 2013. The company specializes in developing a novel nanoparticle platform technology aimed at enhancing drug absorption in challenging-to-penetrate tissues. Its lead candidate, STK-01, targets the absorption issues associated with intravesical chemotherapy for bladder cancer, addressing the limitations of current therapies that often face significant uptake and tolerability challenges. Sitka Biopharma's technology is designed to deliver a higher concentration of the chemotherapeutic agent docetaxel directly into the bladder wall, thereby improving treatment outcomes. The platform is also being explored for future applications in intraperitoneal delivery for ovarian cancer, showcasing its versatility in treating localized diseases where local administration is feasible yet currently ineffective.

Sitka Biopharma Inc. is a preclinical biotechnology company based in Vancouver, Canada, founded in 2013. The company specializes in developing a novel nanoparticle platform technology aimed at enhancing drug absorption in challenging-to-penetrate tissues. Its lead candidate, STK-01, targets the absorption issues associated with intravesical chemotherapy for bladder cancer, addressing the limitations of current therapies that often face significant uptake and tolerability challenges. Sitka Biopharma's technology is designed to deliver a higher concentration of the chemotherapeutic agent docetaxel directly into the bladder wall, thereby improving treatment outcomes. The platform is also being explored for future applications in intraperitoneal delivery for ovarian cancer, showcasing its versatility in treating localized diseases where local administration is feasible yet currently ineffective.